Model nutraceuticals and H. pylori gastric colonization

Helicobacter pylori is a bacterium of major medical interest due to its role in the development of several gastric diseases (chronic gastritis, gastric and duodenal ulcers, gastric adenocarcinoma, MALT lymphoma).

The infection is widespread worldwide, affecting a large part of the population, particularly in developing countries. In France, the prevalence is estimated at between 15 and 30%.

The majority of people infected with H. pylori have no symptoms and will never have any health problems related to the bacterium. The infection remains silent and chronic.

H. pylori carriage and the nutraceutical approach is a growing area of research and interest. Nutraceuticals are not a substitute for approved medical treatment and should always be used as a supplement (i) to support antibiotic treatment (To increase the eradication rate and reduce side effects such as digestive disorders linked to the destruction of intestinal flora by antibiotics) or (ii) as a preventive measure (To help maintain a healthy gastric environment and limit the proliferation of bacteria).

At Vibiosphen, we provide a robust model to support the development of novel nutraceuticals. Our model is designed to generate clinically relevant data that help pharmaceutical, and biotechnology companies accelerate food supplement discovery.
 

Background of Model nutraceuticals and H. pylori gastric colonization

Our murine model of H. pylori gastric colonization is characterized by a stable and persistent bacterial load within the gastric mucosa for up to 28 days post-inoculation. This robust and reproducible colonization period therefore offers a valuable in vivo platform for the comprehensive evaluation of novel interventions, specifically allowing us to assess the impact of nutraceutical compounds.

Mouse Model nutraceuticals and H. pylori gastric colonization

• The primary mouse lineages used in preclinical studies are inbred strains known for their genetic uniformity, which minimizes experimental variability.
  • C57BL/6 mice 
  • BALB/c mice
• Outbred mice, unlike their inbred counterparts, are maintained in large, randomly bred colonies to maximize genetic variation. This heterogeneity makes each mouse genetically unique.
  • CD-1 (also known as ICR) mice
  • Swiss mice
     

Readouts in the model nutraceuticals and H. pylori gastric colonization

• Primary endpoints
  • Mouse monitoring (bodyweight, clinical signs)
  • Quantification gastric carriage (bacterial load)
     
• Secondary endpoints
  • Gut microbiota composition (metagenomic)

• Tissue and sample collection
  • Feces
  • Intestinal segments
  • Blood

Why Choose Vibiosphen?

• Proven expertise in infectious disease research
• Flexible and customized study designs adapted to sponsor requirements (see downloads available as example) 
• Advanced facilities to ensure reliable and reproducible results (BSL2 and BSL3) 
• Strong collaborations with pharmaceutical companies, biotech firms, and academic partners

Vibiosphen combines scientific excellence with industry know-how to deliver actionable preclinical data that drive innovation in infectious disease therapeutics.

Contact Us

If you are developing new treatments or vaccines against pulmonary infections, Vibiosphen can help accelerate your research.

Contact us today to discuss your project and explore how our pulmonary infection models can support your development strategy. 

We will be pleased to facilitate your project by providing a customized study design to your project objectives.